NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The ECA takes this all into account, and there was no cherry picking. Further, patients that had more residual disease in the DCVax-L trial did better than the same patients in the comparable trials. Dr. Liau discusses this in her presentation with Al Musella. The term there is residual disease. And no, none of the patients get ALL of their disease removed, that is the problem with GBM. You can't remove all of the tumor. The numbers of patients with minor or significant residual disease is comparable with the other trials they used for nGBM. For rGBM, it's not relevant. And the independent group that did the SAP and ECA actually calculated for these differences in patients and between trials.